Skip to content
value.today

Selecta Biosciences Inc.

Total raised
$101 M
8 rounds on record
Latest round
$5 M
Dec 2016
First round on record
Mar 2010
Today
Went public
See the company page

Selecta Biosciences Inc. is listed today as Cartesian Therapeutics, Inc.: market value, financials and filings are on its company page.

Funding rounds

8 counted as startup funding, 5 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Selecta Biosciences Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2024$130 MPrivate placement after listing$50 to $250 million

Selecta Biosciences Inc.: Private sale, Jul 2024

Investors in this round

22 investors had bought by the notice of Jul 17, 2024: 22 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 20 investors are named for Selecta Biosciences Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$130 M of $130 M offered
Smallest investment taken
no minimum stated
What was sold
equity, other: common stock and convertible preferred stock convertible into common stock
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$4,969,980
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Blaine Davis · Executive Officer
  • Carsten Brunn · Executive Officer, Director
  • Chris A. Jewell · Executive Officer
  • Emily A. English · Executive Officer
  • Metin A. Kurtoglu · Executive Officer
  • Milos A. Miljkovic · Executive Officer
  • Carrie S. Cox · Director
  • Kemal C. Malik · Director
  • Michael C. Singer · Director
  • Murat C. Kalayoglu · Director
  • Nishan C. de Silva · Director
  • Patrick A. Zenner · Director
  • Timothy A. Springer · Director
  • Timothy C. Barabe · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Blaine Davis, Chief Financial Officer. Source: SEC Form D, newest notice filed Jul 17, 2024. Read the notice at the SEC.

equitySEC
Jul 2020$25 MPrivate placement after listing$10 to $50 million

Selecta Biosciences Inc.: Private sale, Jul 2020

Investors in this round

1 investor had bought by the notice of Aug 18, 2020: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 20 investors are named for Selecta Biosciences Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$25 M of $25 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bradford D. Dahms · Executive Officer
  • Carsten Brunn · Executive Officer, Director
  • Elona Kei Kogan · Executive Officer
  • Lloyd D. Johnston · Executive Officer
  • Stephen Kei Smolinksi · Executive Officer
  • Takashi Kei Kishimoto · Executive Officer
  • Aymeric Kei Sallin · Director
  • Carrie Kei Cox · Director
  • Goran Kei Ando · Director
  • Patrick Kei Zenner · Director
  • Scott Kei Myers · Director
  • Timothy Kei Barabe · Director
  • Timothy Kei Springer · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Bradford D. Dahms, Chief Financial Officer. Source: SEC Form D, newest notice filed Aug 18, 2020. Read the notice at the SEC.

equitySEC
Dec 2019$70 MPrivate placement after listing$50 to $250 million

Selecta Biosciences Inc.: Private sale, Dec 2019

Investors in this round

26 investors had bought by the notice of Jan 2, 2020: 26 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 20 investors are named for Selecta Biosciences Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$70 M of $70 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$4,200,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alison Kei Schecter · Executive Officer
  • Bradford Dahms · Executive Officer
  • Carsten Brunn · Executive Officer, Director
  • Elona Kei Kogan · Executive Officer
  • Lloyd Johnston · Executive Officer
  • Stephen Kei Smolinski · Executive Officer
  • Takashi Kei Kishimoto · Executive Officer
  • Amir Dunseth Nashat · Director
  • Aymeric Dunseth Sallin · Director
  • Carrie Kei Cox · Director
  • Patrick Dunseth Zenner · Director
  • Scott Dunseth Myers · Director
  • Timothy Dunseth Springer · Director
  • Timothy Kei Barabe · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Cantor Fitzgerald LP (CRD 134) · New York, New YorkSold in CA, FL, MA, MN, NY, UT, WA
  • Janney Montgomery Scott LLC (CRD 463) · Philadelphia, PennsylvaniaSold in CA, FL, MA, MN, NY, UT, WA
  • Canaccord Genuity LLC (CRD 1020) · New York, New YorkSold in CA, FL, MA, MN, NY, UT, WA
  • Needham & Company (CRD 16360) · New York, New YorkSold in CA, FL, MA, MN, NY, UT, WA

Signed by Matthew W. Bartholomae, Associate General Counsel. Source: SEC Form D, newest notice filed Jan 2, 2020. Read the notice at the SEC.

equity, optionsSEC
Aug 2019$6 MPrivate placement after listing$2 to $10 million

Selecta Biosciences Inc.: Private sale, Aug 2019

Investors in this round

10 investors had bought by the notice of Sep 4, 2019: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 20 investors are named for Selecta Biosciences Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$6 M of $6 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alison Kei Schecter · Executive Officer
  • Carsten Brunn · Executive Officer, Director
  • Elona Kei Kogan · Executive Officer
  • Lloyd Johnston · Executive Officer
  • Stephen Kei Smolinski · Executive Officer
  • Takashi Kei Kishimoto · Executive Officer
  • Amir Kei Nashat · Director
  • Aymeric Kei Sallin · Director
  • Omid Kei Farokhzad · Director
  • Patrick Kei Zenner · Director
  • Scott D. Myers · Director
  • Timothy Kei Barabe · Director
  • Timothy Kei Springer · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Elona Kogan, General Counsel and Secretary. Source: SEC Form D, newest notice filed Sep 4, 2019. Read the notice at the SEC.

equitySEC
Jun 2017$50 MPrivate placement after listing$50 to $250 million

Selecta Biosciences Inc.: Private sale, Jun 2017

Investors in this round

11 investors had bought by the notice of Jul 11, 2017: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 20 investors are named for Selecta Biosciences Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$50 M of $50 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$2,640,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Kei Abraham · Executive Officer
  • David Kei Siewers · Executive Officer
  • Earl Kei Sands · Executive Officer
  • Lloyd Johnston · Executive Officer
  • Peter Kei Keller · Executive Officer
  • Takashi Kei Kishimoto · Executive Officer
  • Werner Cautreels · Executive Officer, Director
  • Amir Barton Nashat · Director
  • Aymeric Barton Sallin · Director
  • Omid C. Farokhzad · Director
  • Patrick Barton Zenner · Director
  • Peter Barton Hutt · Director
  • Timothy Barton Springer · Director
  • Timothy C. Barabe · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Stifel, Nicolaus & Company Incorporated (CRD 793) · San Francisco, CaliforniaSold in CA, CT, FL, MA, NY

Signed by Werner Cautreels, President and CEO. Source: SEC Form D, newest notice filed Jul 11, 2017. Read the notice at the SEC.

equity, optionsSEC
Dec 2016$5 MNo. 8$2 to $10 million

Selecta Biosciences Inc.: Raise no. 8, Dec 2016

Investors in this round

1 investor had bought by the notice of Dec 14, 2016: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 20 investors are named for Selecta Biosciences Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Kei Abraham · Executive Officer
  • David Kei Siewers · Executive Officer
  • Earl Kei Sands · Executive Officer
  • Lloyd Johnston · Executive Officer
  • Peter Kei Keller · Executive Officer
  • Takashi Kei Kishimoto · Executive Officer
  • Werner Cautreels · Executive Officer, Director
  • Amir M. Nashat · Director
  • Aymeric M. Sallin · Director
  • Carl C. Gordon · Director
  • Edwin M. Kania, Jr. · Director
  • Omid C. Farokhzad · Director
  • Peter Barton Hutt · Director
  • Timothy C. Barabe · Director
  • Timothy M. Springer · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Werner Cautreels, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 14, 2016. Read the notice at the SEC.

equitySEC
Aug 2015$37 MNo. 7$10 to $50 million

Selecta Biosciences Inc.: Raise no. 7, Aug 2015

Investors in this round

19 investors had bought by the notice of Sep 10, 2015: 19 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 20 investors are named for Selecta Biosciences Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$37 M of $41 M offered; $3 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David M. Abraham · Executive Officer
  • David M. Siewers · Executive Officer
  • Earl Kei Sands · Executive Officer
  • Lloyd M. Johnston · Executive Officer
  • Peter Kei Keller · Executive Officer
  • Takashi Kei Kishimoto · Executive Officer
  • Werner Cautreels · Executive Officer, Director
  • Amir M. Nashat · Director
  • Aymeric M. Sallin · Director
  • Carl Gordon · Director
  • Edwin M. Kania, Jr. · Director
  • George M. Siber · Director
  • Leysan M. Shaydullina · Director
  • Omid Farokhzad · Director
  • Peter Barton Hutt · Director
  • Robert M. Langer · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David Abraham, General Counsel. Source: SEC Form D, newest notice filed Sep 10, 2015. Read the notice at the SEC.

equity, optionsSEC
Apr 2015$6 MNo. 6$2 to $10 million

Selecta Biosciences Inc.: Raise no. 6, Apr 2015

Investors in this round

12 investors had bought by the notice of Apr 23, 2015: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 20 investors are named for Selecta Biosciences Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$6 M of $8 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David M. Abraham · Executive Officer
  • David M. Siewers · Executive Officer
  • Lloyd M. Johnston · Executive Officer
  • Peter Kei Keller · Executive Officer
  • Takashi Kei Kishimoto · Executive Officer
  • Werner Cautreels · Executive Officer, Director
  • Amir M. Nashat · Director
  • Aymeric M. Sallin · Director
  • Carl Gordon · Director
  • Edwin M. Kania, Jr. · Director
  • George M. Siber · Director
  • Omid Farokhzad · Director
  • Peter Barton Hutt · Director
  • Robert M. Langer · Director
  • Yuriy M. Udaltsov · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David Abraham, General Counsel. Source: SEC Form D, newest notice filed Apr 23, 2015. Read the notice at the SEC.

debt, optionsSEC
Aug 2014$4 MNo. 5$2 to $10 million

Selecta Biosciences Inc.: Raise no. 5, Aug 2014

Investors in this round

11 investors had bought by the notice of Aug 28, 2014: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 20 investors are named for Selecta Biosciences Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
$100,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Massachusetts

People named in the notice

  • David M. Abraham · Executive Officer
  • David M. Siewers · Executive Officer
  • Werner Cautreels · Executive Officer, Director
  • Amir M. Nashat · Director
  • Aymeric M. Sallin · Director
  • Carl Gordon · Director
  • Edwin M. Kania, Jr. · Director
  • George M. Siber · Director
  • Omid Farokhzad · Director
  • Peter Barton Hutt · Director
  • Robert M. Langer · Director
  • Yuriy M. Udaltsov · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David Siewers, Treasurer. Source: SEC Form D, newest notice filed Aug 28, 2014. Read the notice at the SEC.

equitySEC
Jul 2014$6 MNo. 4$2 to $10 million

Selecta Biosciences Inc.: Raise no. 4, Jul 2014

Investors in this round

2 investors had bought by the notice of Jul 15, 2014: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 20 investors are named for Selecta Biosciences Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$6 M of $6 M offered
Smallest investment taken
$3,000,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Massachusetts

People named in the notice

  • David M. Abraham · Executive Officer
  • David M. Siewers · Executive Officer
  • Werner Cautreels · Executive Officer, Director
  • Amir M. Nashat · Director
  • Aymeric M. Sallin · Director
  • Carl Gordon · Director
  • Edwin M. Kania, Jr. · Director
  • George M. Siber · Director
  • Omid Farokhzad · Director
  • Peter Barton Hutt · Director
  • Robert M. Langer · Director
  • Yuriy M. Udaltsov · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David Siewers, Treasurer. Source: SEC Form D, newest notice filed Jul 15, 2014. Read the notice at the SEC.

equitySEC
Apr 2014$5 MNo. 3$2 to $10 million

Selecta Biosciences Inc.: Raise no. 3, Apr 2014

Investors in this round

11 investors had bought by the notice of Apr 9, 2014: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 20 investors are named for Selecta Biosciences Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$5 M of $10 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Massachusetts

People named in the notice

  • David M. Abraham · Executive Officer
  • David M. Siewers · Executive Officer
  • Werner Cautreels · Executive Officer, Director
  • Amir M. Nashat · Director
  • Aymeric M. Sallin · Director
  • Carl Gordon · Director
  • Edwin M. Kania, Jr. · Director
  • George M. Siber · Director
  • Omid Farokhzad · Director
  • Peter Barton Hutt · Director
  • Robert M. Langer · Director
  • Yuriy M. Udaltsov · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David Siewers, Treasurer. Source: SEC Form D, newest notice filed Apr 9, 2014. Read the notice at the SEC.

equitySEC
Nov 2011$22 MNo. 2$10 to $50 million

Selecta Biosciences Inc.: Raise no. 2, Nov 2011

Investors in this round

16 investors had bought by the notice of Nov 17, 2011: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 20 investors are named for Selecta Biosciences Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$22 M of $22 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Massachusetts

People named in the notice

  • David Barton Siewers · Executive Officer
  • Werner Cautreels · Executive Officer, Director
  • Amir Barton Nashat · Director
  • Aymeric Barton Sallin · Director
  • Carl Gordon · Director
  • Cole Douglas · Director
  • George Barton Siber · Director
  • Omid Farokhzad · Director
  • Peter Barton Hutt · Director
  • Robert Barton Langer · Director
  • Yuriy Barton Udaltsov · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “None other than salaries and bonuses in the ordinary course of business.”

Signed by David Siewers, Vice President of Finance. Source: SEC Form D and 1 amendment, newest notice filed Nov 17, 2011. Read the notice at the SEC.

equitySEC
Mar 2010$15 MNo. 1$10 to $50 million

Selecta Biosciences Inc.: Raise no. 1, Mar 2010

Investors in this round

14 investors had bought by the notice of Apr 6, 2010: 14 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 20 investors are named for Selecta Biosciences Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$15 M of $15 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Massachusetts

People named in the notice

  • Robert L. Bratzler · Executive Officer, Director
  • Amir L. Nashat · Director
  • Aymeric L. Sallin · Director
  • Carl L. Gordon · Director
  • Douglas L. Cole · Director
  • George Barton Siber · Director
  • Omid L. Farokhzad · Director
  • Peter Barton Hutt · Director
  • Robert S. Langer, Jr. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “None other than salaries and bonuses in the ordinary course of business.”

Signed by Robert L. Bratzler, Executive Chairman. Source: SEC Form D, newest notice filed Apr 6, 2010. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Cartesian Therapeutics, Inc., its revenue in fiscal 2025 came from these business segments: Operating $2.80 million (100%).

    Annual report (SEC XBRL) · Dec 2025

  • Selecta Biosciences Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2024).

    SEC Form D · Jul 2024

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jul 2024

Products and services#

No products or services of Selecta Biosciences Inc. are on record.

Investors#

20 named in official filings. Open an investor to see everything it has backed.

Investors in Selecta Biosciences Inc.
InvestorKindAmountRoundRoleSource
Flagship Ventures 2007 General Partner LLCVenture capitalnot statednot statedHeld Series A, B, C, D and E preferred stock, 10% owner, director (Form 3, 2016)SEC Form 3
Flagship Ventures Fund 2007, L.P.Venture capitalnot statednot statedHeld Series A, B, C, D and E preferred stock, 10% owner, director (Form 3, 2016)SEC Form 3
Leukon Investments, LPFund or asset managernot statednot statedHeld Series B, C, D and E preferred stock, 10% owner, director (Form 3, 2016)SEC Form 3
Nanodimension Limited PartnershipFund or asset managernot statednot statedHeld Series B, C, D and E preferred stock, 10% owner (Form 3, 2016)SEC Form 3
Nanodimension Management LtdFund or asset managernot statednot statedHeld Series B, C, D and E preferred stock, 10% owner (Form 3, 2016)SEC Form 3
Orbimed Advisors LLCFund or asset managernot statednot statedHeld Series C, D and E preferred stock, 10% owner, director (Form 3, 2016)SEC Form 3
OrbiMed Capital GP III LLCFund or asset managernot statednot statedHeld Series C, D and E preferred stock, 10% owner, director (Form 3, 2016)SEC Form 3
Osage Partners, LLCFund or asset managernot statednot statedHeld Series E preferred stock, 10% owner (Form 3, 2016)SEC Form 3
Osage University GP II, L.P.Fund or asset managernot statednot statedHeld Series E preferred stock, 10% owner (Form 3, 2016)SEC Form 3
Osage University Partners II, L.P.Fund or asset managernot statednot statedHeld Series E preferred stock, 10% owner (Form 3, 2016)SEC Form 3
Polaris Venture Management Co. V, L.L.C.Venture capitalnot statednot statedHeld Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2016)SEC Form 3
Polaris Venture Partners Entrepreneurs' Fund V, L.P.Venture capitalnot statednot statedHeld Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2016)SEC Form 3
Polaris Venture Partners Founders' Fund V, L.P.Venture capitalnot statednot statedHeld Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2016)SEC Form 3
Polaris Venture Partners Special Founders' Fund V, L.P.Venture capitalnot statednot statedHeld Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2016)SEC Form 3
Polaris Venture Partners V, L.P.Venture capitalnot statednot statedHeld Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2016)SEC Form 3
RusnanoPersonnot statednot statedHeld Series D, E and SRN preferred stock, 10% owner (Form 3, 2016)SEC Form 3
Selecta RKFN, Ltd.Companynot statednot statedHeld Series SRN preferred stock, 10% owner (Form 3, 2016)SEC Form 3
Seven One Eight Three Four Irrevocable TrustOthernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2023)SEC Form 3
TAS Partners, LLCFund or asset managernot statednot statedHeld Series B, C, D and E preferred stock, 10% owner, director (Form 3, 2016)SEC Form 3
VTB Capital I2BF Netherlands, B.V.Fund or asset managernot statednot statedHeld Series SRN preferred stock, 10% owner (Form 3, 2016)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 8 rounds above had up to 19 investors.

Largest shareholders today

Institutions holding Cartesian Therapeutics, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Selecta Biosciences Inc.
NameRoleNamed in
Blaine DavisExecutive officerJul 2024
Carsten BrunnExecutive officerJul 2024
Chris A. JewellExecutive officerJul 2024
Emily A. EnglishExecutive officerJul 2024
Metin A. KurtogluExecutive officerJul 2024
Milos A. MiljkovicExecutive officerJul 2024
Bradford D. DahmsExecutive officerAug 2020
Elona Kei KoganExecutive officerAug 2020
Lloyd D. JohnstonExecutive officerAug 2020
Stephen Kei SmolinksiExecutive officerAug 2020
Takashi Kei KishimotoExecutive officerAug 2020
Alison Kei SchecterExecutive officerJan 2020
Bradford DahmsExecutive officerJan 2020
Lloyd JohnstonExecutive officerJan 2020
Stephen Kei SmolinskiExecutive officerJan 2020
David Kei AbrahamExecutive officerJul 2017
David Kei SiewersExecutive officerJul 2017
Earl Kei SandsExecutive officerJul 2017
Peter Kei KellerExecutive officerJul 2017
Werner CautreelsExecutive officerJul 2017
David M. AbrahamExecutive officerSep 2015
David M. SiewersExecutive officerSep 2015
Lloyd M. JohnstonExecutive officerSep 2015
David Barton SiewersExecutive officerNov 2011
Robert L. BratzlerExecutive officerApr 2010
Carrie S. CoxDirectorJul 2024
Carsten BrunnDirectorJul 2024
Kemal C. MalikDirectorJul 2024
Michael C. SingerDirectorJul 2024
Murat C. KalayogluDirectorJul 2024
Nishan C. de SilvaDirectorJul 2024
Patrick A. ZennerDirectorJul 2024
Timothy A. SpringerDirectorJul 2024
Timothy C. BarabeDirectorJul 2024
Aymeric Kei SallinDirectorAug 2020
Carrie Kei CoxDirectorAug 2020
Goran Kei AndoDirectorAug 2020
Patrick Kei ZennerDirectorAug 2020
Scott Kei MyersDirectorAug 2020
Timothy Kei BarabeDirectorAug 2020

About

Company in Watertown, United States.

Went public since 2016. Its SEC number is that of a company listed on a stock exchange.